Supreme Court tosses out anti-Amgen ruling in employee case; Big Pharma companies are top MBA recruiters;

@FiercePharma: PetMed marketing overhaul pays off as orders continue to rise in Q3. Article | Follow @FiercePharma

@EricPFierce: EMA suspends Hubei Hongyuan Pharmaceutical after Czech inspectors find dust-covered plant and equipment. ICYMI fron FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Amgen's Repatha wins first PCSK9 OK in Japan. Article | Follow @CarlyHFierce

> Amgen has scored a victory thanks to the U.S. Supreme Court, which on Monday tossed out a ruling in favor of current and former employees who say they lost money by investing in the pharmaceutical company's own stock-ownership plan. Report

> As the debate over drug prices escalated last year, the pharma industry trade group PhRMA hiked its lobbying spending to $18.32 million, up from $16.51 million in 2014. Report

> Denmark-based Novo Nordisk ($NVO) is staffing up in Iran and continuing work on an expanded manufacturing presence as sanctions lift in the country. Report

> Allergan ($AGN) has won expanded FDA approval for Botox as a treatment for muscle spasticity; the new nod for the drug, best known as a cosmetic treatment, covers muscles in the ankle and toes. Release

> The Philippines' labor secretary has called a meeting between the union and management of Sanofi Aventis, and the medical representatives are calling on the country's Department of Labor and Employment to broker a "fair deal." Report

Medical Device News

@FierceMedDev: U.S. regulators nix $3B Philips lighting sale, complicating HealthTech shift. Article | Follow @FierceMedDev

@EmilyWFierce: It's not bedtime yet for J&J in false advertising lawsuit over baby products. FiercePharmaMarketing story | Follow @EmilyWFierce

> Theranos flagged by CMS for serious problems at California lab: WSJ. More

> German radiosurgery player Brainlab invests $7M+ in Jan Medical for portable concussion Dx. Story

> Wound care company ConvaTec laying off 250 in North Carolina after failing to find M&A suitor. Article

Biotech News

@FierceBiotech: Hedge fund's attack on troubled Zafgen draws blood. Story | Follow @FierceBiotech

@JohnCFierce: $ZFGN down 10% on short attack from Kerrisdale. More | Follow @JohnCFierce

@DamianFierce: the $SRPT cancellation robbed us of a situation in which Ed Kaye and Janet Woodcock are trapped in White Oak and have to unite to survive. | Follow @DamianFierce

> Soon-Shiong's NantCell raises another $57M for immuno-oncology work. Report

> Merck teams with Affimed on immuno-oncology combo. Item

> Editas tests CRISPR/Cas9 enthusiasm--and a turbulent market--with $122M IPO. Article

Animal Health News

> Bird flu losses mount as U.S., Mexico, Canada sign historic pact to control outbreaks. More

> Ceva enters pact with Zoion to develop treatment for dry eye in dogs. Report

> Pharma leaders declare war on antibiotic resistance at Davos. Item

> PetMed marketing overhaul pays off as orders continue to rise in Q3. Story

> Veterinarian turns dog owner's tragedy into cloud-based EHR for pets. Article

Biotech IT News

> BioClinica buys Clinverse to add clinical trial financial management software. More

> GSK scientists accused of data theft in low-tech cybercrime case. Report

> Cedars-Sinai to test Fitbit activity trackers in cancer clinical trial. Item

> Takeda engages Broad for genomic analysis of patient samples from PhIII cancer trial. Story

> Big Pharma consortium rolls out clinical trial investigator platform. Article

Pharma Marketing News

> Synchronized dancers jazz up Reckitt Benckiser's new MegaRed pitch. More

> Fishing for market share, Boehringer Ingelheim casts a new campaign for Pradaxa. Report

> Camera-ready Pfizer and J&J top pharma list of TV ad spenders for 2015. Story

> Oxford Pharmascience scouts marketing partners for new pain meds. Item

> It's not bedtime yet for J&J in false advertising lawsuit over baby products. Article

And Finally... Big Pharma companies are top MBA recruiters, a recent report shows. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.